Nanion Corporate Blog

 

20.09.2019: Recent publication on the downregulation of miR-146a

We as Nanion Technologies would like to congratulate Li Shen and the co-authors of this insightful paper. The paper shows that sunitinib downregulates miR-146a, thereby contributing to cardiac contractile dysfunction by targeting PLN and ANK2. miR-146a could thus, be a useful protective agent against sunitinib-induced cardiac dysfunction. We are honoured that the group from the Pharmacology department of the Hebei Medical University, China used among other assays, the Cardioexcyte 96 for this study.

Download the publication here

Back to Overview

Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok